Macrophage heterogeneity, phenotypes, and roles in renal fibrosis

Slides:



Advertisements
Similar presentations
Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup
Advertisements

Current status of end-stage renal disease care in India and Pakistan
Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors
Volume 149, Issue 4, Pages (October 2015)
Immune mediators of tissue remodelling and lung function impairment in tuberculosis. Immune mediators of tissue remodelling and lung function impairment.
Volume 149, Issue 4, Pages (October 2015)
Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis  Hans-Joachim Anders, Mi Ryu 
Highlights of a workshop to discuss targeting inflammation in cystic fibrosis  Katharine H. Banner, Hugo De Jonge, Stuart Elborn, Ellena Growcott, Erich.
S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F
David C.H. Harris, Sophie Dupuis, William.G. Couser, John Feehally 
Volume 85, Issue 4, Pages (April 2014)
NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a non-canonical manner  Hans-Joachim Anders, Maciej.
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
The Th17 immune response in renal inflammation
Volume 81, Issue 9, Pages (May 2012)
Summary of Recommendation Statements
NAFLD, Obesity, and Bariatric Surgery
Toll-like receptor activation: from renal inflammation to fibrosis
Tipping the balance from angiogenesis to fibrosis in CKD
Roles for Chemokines in Liver Disease
David J. Nikolic-Paterson, Shuang Wang, Hui Yao Lan 
Current status of end-stage renal disease care in India and Pakistan
Kidney transplantation in a low-resource setting: Nigeria experience
Aging-related inflammation in osteoarthritis
Yiping Wang, Yuet-Ching Tay, David C.H. Harris  Kidney International 
Volume 63, Issue 3, Pages (March 2003)
Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation  Adriana S. Dusso  Kidney International Supplements 
EGFR signaling in renal fibrosis
Burden of chronic kidney disease: North Africa
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Volume 85, Issue 3, Pages (March 2014)
EGFR (Trans)activation Mediates IL-8 and Distinct Human Antimicrobial Peptide and Protein Production following Skin Injury  Amanda S. Büchau  Journal.
Pro-endometriotic niche in endometriosis
Hepatic fibrosis: Concept to treatment
Programmed anti-inflammatory macrophages protect against AKI and promote repair through trophic actions  Christof Westenfelder  Kidney International 
Volume 86, Issue 4, Pages (October 2014)
Comorbidity and confounding in end-stage renal disease
Volume 70, Issue 11, Pages (December 2006)
Reciprocal functions of hepatocyte growth factor and transforming growth factor-β1 in the progression of renal diseases: A role for CD44?  Sandrine Florquin,
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Claudine S. Bonder, Lisa M. Ebert  Kidney International 
Volume 71, Issue 6, Pages (March 2007)
Saulo Klahr, Jeremiah J. Morrissey  Kidney International 
Volume 70, Issue 12, Pages (December 2006)
Osteopontin in diabetic nephropathy: signpost or road?
Therapeutic strategies in inflammasome mediated diseases of the liver
Methods for guideline development
CD4+ T cells: a potential player in renal fibrosis
Florian E. Togel, Christof Westenfelder 
Apoptosis in ischemic renal injury: Roles of GTP depletion and p53
Why is proteinuria an ominous biomarker of progressive kidney disease?
Volume 82, Issue 9, Pages (November 2012)
Basophils and mast cells in renal injury
Ischemic acute renal failure: An inflammatory disease?
Current status of maintenance hemodialysis in Beijing, China
Stephen O'Neill, Jeremy Hughes  Kidney International 
Molecular mechanisms of renal hypertrophy: Role of p27Kip1
Volume 56, Pages S84-S87 (November 1999)
Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes
Ann Marie Schmidt, Kathryn J. Moore  Cell Metabolism 
Is complement a target for therapy in renal disease?
David A. Ferenbach, David C. Kluth, Jeremy Hughes  Kidney International 
Volume 86, Issue 5, Pages (November 2014)
Sundararaman Swaminathan, Matthew D. Griffin  Kidney International 
Adiponectin: good, bad, or just plain ugly?
Volume 75, Issue 6, Pages (March 2009)
Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor  Senthilkumar Alagesan, Matthew D. Griffin 
Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?
Familial phenotype differences in PKD11
Influence of the tumor microenvironment on FL
Presentation transcript:

Macrophage heterogeneity, phenotypes, and roles in renal fibrosis Qi Cao, Yiping Wang, David C.H. Harris  Kidney International Supplements  Volume 4, Issue 1, Pages 16-19 (November 2014) DOI: 10.1038/kisup.2014.4 Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 1 Macrophage phenotype and function are critical determinants of kidney fibrosis. In response to ongoing injury, activated pro-inflammatory macrophages (M1) enhance kidney inflammation by secreting pathogenic mediators, resulting in kidney fibrosis in the late stage of disease. M1 macrophages also directly induce kidney fibrosis by secreting profibrotic factors, such as matrix metalloprotease (MMP)-9. In contrast, anti-inflammatory macrophages (M2) suppress kidney inflammation by releasing anti-inflammatory mediators interleukin (IL)-10 and transforming growth factor-beta (TGF-β), resulting in reduced kidney fibrosis. In addition, TGF-β produced by M2 macrophages promotes kidney fibrosis directly. Therefore, the net effect of M2 macrophages on kidney fibrosis is uncertain. CCL2, chemokine ligand 2; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-alpha. Kidney International Supplements 2014 4, 16-19DOI: (10.1038/kisup.2014.4) Copyright © 2014 International Society of Nephrology Terms and Conditions